Background. Recent literature has highlighted methicillin-resistant Staphylococcus aureus (MRSA) nasal screening as a possible antimicrobial stewardship program tool for avoiding unnecessary empiric MRSA therapy for pneumonia, yet current guidelines recommend MRSA therapy based on risk factors. The objective of this meta-analysis was to evaluate the diagnostic value of MRSA nasal screening in MRSA pneumonia.
Current guidelines for the treatment of pneumonia published by the American Thoracic Society and Infectious Diseases Society of America (IDSA) recommend empiric methicillin-resistant Staphylococcus aureus (MRSA) coverage in at-risk patients, yet MRSA pneumonia has a low prevalence [1, 2] . Although initiating appropriate empiric antibiotics in a timely manner is critical, prescribers are often challenged in which patients to initiate anti-MRSA coverage to and when to deescalate therapy. Current guidelines do not provide guidance on deescalation before the availability of respiratory culture results, which may take up to 96 hours to process, or in their absence. As a result, anti-MRSA therapy, such as vancomycin, is frequency continued, contributing to unfavorable consequences of antimicrobial overuse, including increased risk of adverse events, antimicrobial resistance, drug-drug interactions, and increased expense [3] .
S. aureus, including MRSA, is a common colonizer of the nares. The absence of MRSA nares colonization has reported to be a negative predictor of MRSA pulmonary infections, specifically pneumonia. Traditionally, nares surveillance for MRSA is used for infection control and prevention purposes. However, recent literature has highlighted MRSA nasal screening as a useful antimicrobial stewardship screening test for avoiding unnecessary empiric MRSA therapy, including vancomycin [4, 5] . The objective of the current meta-analysis was to evaluate the diagnostic value of MRSA nasal screening in ruling out potential MRSA pneumonia.
We used the following search string: (methicillin-resistant Staphylococcus aureus OR MRSA) AND (nasal OR nares) AND (pneumonia OR respiratory OR lower respiratory tract infections). Citation titles and abstracts were reviewed for relevance, and full-text reviews were then performed on all potentially relevant studies. Bibliographies of included articles were reviewed for additional studies of relevance. Conference proceedings from IDWeek, the Interscience Conference on Antimicrobial Agents and Chemotherapy, and the European Congress of Clinical Microbiology and Infectious Diseases from 2007 to 2016 were also reviewed, using the keywords "nares" and "nasal" to identify unpublished studies.
Inclusion and Exclusion Criteria
Studies were included if they contained information on both positive rates of MRSA nasal surveillance screening using either culture or polymerase chain reaction (PCR) and reported the rates of culture confirmed MRSA pneumonia for community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), healthcare-associated pneumonia (HCAP), or ventilator-associated pneumonia (VAP). Studies were excluded if they were non-English, used only MRSA surveillance culture studies from other body sites (eg, throat swab samples), or zero-event studies (eg, absence of MRSA pneumonia diagnosed).
Outcomes
Outcomes evaluated for the clinical utility of MRSA nasal screening for predicting MRSA pneumonia included the performance characteristics of sensitivity, specificity, diagnostic odds ratios, likelihood ratios, positive predictive values (PPVs), and negative predictive values (NPVs). Factors affecting test performance and heterogeneity among studies were also assessed.
Data Extraction and Quality Assessment
Two investigators (D. M. P. and T. T. T.) independently reviewed the literature. Differences in article selection were resolved by consensus. Each investigator evaluated the included studies for possible sources of bias using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) checklist [6] . Data were extracted from the studies on rates of positive MRSA nasal surveillance screens, rates of MRSA pneumonia, study designs, setting, patient population and sample size, pneumonia classification and assessment definitions if present, respiratory culture type, and timing of surveillance screens.
Data Analysis
Performance characteristics were evaluated using a bivariate model for diagnostic meta-analysis to calculate the pooled sensitivities, specificities, diagnostic odds ratio, likelihood ratios, PPVs, and NPVs. Random-effects modeling was used on the assumption of heterogeneity in measurements among studies. PPVs and NPVs were calculated using the pooled MRSA pneumonia prevalence among the included studies overall and by pneumonia type for CAP/HCAP, HAP, and VAP. Pooled prevalence was calculated using a random-effects model and excluded studies of only S. aureus pneumonia cohorts. Publication bias was assessed with the Deeks test [7] .
Possible sources of heterogeneity were evaluated using meta-regression. Heterogeneity was determined with a Cochran Q statistic , with results considered significant at P < .10. Analyses were performed using Stata software version 14 (StataCorp) with the metandi and metaprop_one packages for pooled bivariate modeling and pooled prevalences, respectively. The midas package was also used for evaluating publication bias and heterogeneity. Review Manager software (version 5.3; The Cochrane Collaboration) was used to produce summary plots. This systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary Table S1 ) [8] .
RESULTS
The literature search resulted in 500 studies meeting key word criteria ( Figure 1 ). After removal of duplicates, we reviewed titles and abstracts for 371 studies. Studies not relevant to our search were removed, yielding 69 studies for full review. Fulltext review identified 18 nonrelevant studies, 21 studies with incomplete data, and 8 that did not meet inclusion criteria. In total, data were extracted from 22 studies for analysis, comprising 5163 patients.
Characteristics of the included studies are shown in Table 1 [4, 5, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Of the 22 studies, 18 (81.8%) were retrospective studies, 3 (13.6%) were prospective cohorts, and the study design for 1 (4.5%) was not reported; 7 of the 22 studies (31.8%) were conference proceedings. Although most studies were conducted at teaching hospitals, 1 (4.5%) was conducted in a federal hospital, and the hospital setting was nor reported in 5 (22.7%). Among the 22 studies, only 11 (50%) reported pneumonia classification; 3 studies (27.3%) evaluated CAP, HCAP, and VAP, 5 (45.5%) evaluated only VAP, 2 (18.2%) evaluated CAP/HCAP, and 1 (9.1%) evaluated "nosocomial" pneumonia.
The criteria used to diagnose pneumonia varied among the studies, with only 2 of 22 studies (9.1%) not reporting the criteria used. A majority of studies included radiographic, respiratory cultures, and clinical criteria to confirm diagnosis of pneumonia ( Table 1 ). The MRSA nares surveillance methods used also varied among studies. PCR was used to detect MRSA in the nares in 11 studies (50%), culture-based identification was used in 4 (18.2%), 1 study (4.5%) used both PCR and culture-base identification, and the remaining studies did not specify the detection method (27.3%). The timing of obtaining MRSA nares surveillance culture was defined in 21 of 22 studies (95.5%). More than half of the studies obtained an MRSA nares surveillance culture at admission to the hospital or the intensive care unit or within 24 hours of admission.
Pooled Prevalence and Diagnostic Performance
The pooled overall prevalence of MRSA pneumonia was 10% (95% confidence interval [CI], 8%-13%; I 2 = 89.6%; P < .001) (Supplementary Figure S1 ). For VAP, the pooled prevalence was 8% (95% CI, 5%-11%; I 2 = 49.9%; P = .14 and included only 3 of the 5 studies meeting criteria for analysis [9, 19, 22] . The prevalence was not conducted for CAP/HCAP, because only 2 studies met criteria and thus a pooled prevalence was not evaluated. Individual prevalence in those studies was 13.0% and 7.1% [4, 11] . Summarized results of the meta-analysis are shown in Table 2 . For all types of pneumonia, the sensitivity, specificity, PPV, and NPV of MRSA nares screen to predict MRSA pneumonia were 70.9% (95% CI, 58.8%-80.6%), 90.3% (86.1%-93.3%), 44.8%, and 96.5%, respectively. For CAP/HCAP, the sensitivity, specificity, PPV, and NPV of the MRSA nares screen were higher at 85% (95% CI, 59.7%-95.6%), 92.1% (81.5%-96.9%), 56.8%, and 98.1%, respectively. However, for VAP the sensitivity and PPV were lowest, at 40.3% (95% CI, 17.4%-68.4%) and 35.7%, respectively; the specificity and NPV for VAP were 93.7% (77.1%-98.4%) and 94.8%, respectively. Supplementary Figure S2 shows the summary ROC curves by pneumonia type.
Heterogeneity
Meta-regression evaluations of the bivariate model for sources of heterogeneity suggested possible heterogeneity. In particular, heterogeneity was identified among prospective versus retrospective studies (P = .01), comparing PCR with other methods (P = .01), testing timing at admission with or without repeated tested, as compared with other timing (P = .02), and VAP studies compared with studies of other types of pneumonia (P = .03) ( Table 3) .
Publication Bias and Quality Assessments
Publication bias, evaluated using the Deeks funnel plot asymmetry test, did not show statistical significance (P = .85), reflecting symmetry to the data and a low probability of publication bias (Supplementary Figure S3 Figure S4 ) , the majority (>90%) of studies had a low risk of bias among all domains except the reference standard, with 59% of studies having a low risk of bias.
DISCUSSION
The use of MRSA nasal screens as a tool to guide deescalation of empiric anti-MRSA therapy was not included in the recent IDSA HAP/VAP guidelines, which recommend that empiric anti-MRSA therapy be given in a significant proportion of patients who have pneumonia [1] . Thus, many patients are exposed to unnecessary antimicrobial therapy, leading to increased potential for adverse drug reactions, other drug effects, unnecessary drug costs, and increased costs of drug administration and monitoring [29] . However, several hospitals have already implemented stewardship practices that discontinue anti-MRSA antibiotics, especially vancomycin, based on negative results MRSA nasal screen results [4, 5, 13, 30, 31] . Clinical outcomes, including mortality rates, have been noted to be similar among patients with therapy deescalations derived from MRSA nasal screens [11, 30] . A recent study using this deescalation approach demonstrated a decrease in MRSA therapy by approximately 2 days (P < .001) and reduced vancomycin serum level monitoring and dose adjustments by nearly 3-fold (P = .02), without a significant difference in clinical outcomes [31] . Another recent study observed a cost reduction of $108 per patient for vancomycin medication costs and trough levels by using MRSA nasal screens for deescalation [5] . The relative cost of nasal S. aureus screening is minimal, providing an attractive way for antimicrobial stewardship programs (ASPs) to reduce unwarranted vancomycin therapy. To our knowledge, ours is the first meta-analysis to evaluate the diagnostic value of MRSA nasal screens in ruling out MRSA pneumonia. Diagnostics odds ratio, the odds of positivity in disease relative to positivity in nondisease, reflected best overall performance among patients with CAP/HCAP [32] . These data can also be noted by the positive and negative likelihood ratios, ratios of positive and negative tests among Abbreviations: CAP, community-acquired pneumonia; CI, confidence interval; DOR, diagnostic odds ratio; HCAP, healthcare-associated pneumonia; LR, likelihood ratio; MRSA, methicillin-resistant Staphylococcus aureus; NPV, negative predictive value; PPV, positive predictive value; VAP, ventilator-associated pneumonia. Abbreviations: PCR, polymerase chain reaction, QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies; VAP, ventilator-associated pneumonia. a "Other" signifies a category different from the reference category, including data not reported.
diseased to the same result among nondiseased patients, with CAP/HCAP. However, we found that owing to the low PPV overall and in subsets by pneumonia type (CAP/HCAP, VAP), positive MRSA nares screens do not have predictive value in the diagnosis of MRSA pneumonia. However, the high NPV in our analysis supports the use of MRSA nasal screens as an ASP tool to rule out MRSA pneumonia. Conversely, we observed a low sensitivity (40.3%) in VAP suggesting a low utility in ruling out VAP MRSA pneumonia, probably related to artificial airways serving as an additional source of MRSA to the nasal passage.
The limitations in VAP were consistent during our analyses for sources of heterogeneity. Notably among bivariate analyses of heterogeneity, PCR testing performance was preferable. This is intuitive, because previous data have reflected improved performance of PCR compared with other methods, such as chromogenic culture; however, PCR is more expensive, at approximately $26 per test versus only $7 per test for chromogenic culture [33] . Beyond cost and performance, the time to result should also be considered, because PCR can provide actionable results for discontinuation of anti-MRSA therapy within 2 hours, which may take 2 days with culture-based testing. Finally, the timing of testing was associated with heterogeneity and is important to take into account when considering the clinical use of these surveillance tests.
Reported MRSA pneumonia rates are quite variable, ranging from <1% to 56% depending on the pneumonia criteria, although higher estimates may be attributable to sampling bias [11, 34] . We found an overall pooled MRSA pneumonia prevalence of 10%. This infrequent cause of pneumonia is accompanied by a clinical presentation, which includes a high severity score and may include acute onset of high fever, chills, severe hypoxemia, hypotension, cyanosis, bilateral rapid thick-walled cavitation, or hemoptysis [35, 36] .
In addition to clinical evaluations, a possible approach for routine use of MRSA nasal screens by ASPs was noted by one of the aforementioned studies, which allowed for a per-protocol order of the MRSA nasal screen test by staff pharmacists in patients prescribed linezolid or vancomycin for possible or confirmed pneumonia as an extension of their hospital-approved vancomycin dosing protocol [31] . These results were flagged for their review and discussed with the prescribing provider if a potential deescalation opportunity occurred. This approach is consistent with data suggesting that nasal screening may occur after initiation of therapy, because MRSA persists in the respiratory tract during the first few days of therapy [4] . Alternatively, if incidental MRSA screen results are known within a week before diagnosis of pneumonia, these would be useful in discontinuing or not initiating anti-MRSA therapy [5, 11] .
Notably, MRSA screens for therapy decisions should be avoided in patients with recent nasal decolonization before screening and MRSA infection within 30 days before admission [5] . In patients with structural lung disease (eg, cystic fibrosis or bronchiectasis), MRSA nares screens may be discordant because colonization occurs more frequently in the lower respiratory tract and therefore should also be avoided. Moreover, in critically ill intensive care unit patients, more cautious deescalations may be considered with deescalations at 48 hours, because 98% of positive blood cultures for Staphylococcus occur within this time [37] .
Our meta-analysis has limitations. Most of these data are from retrospective studies, which may be associated with increased bias, such as sampling bias of patients with available culture data, which probably occurred and would explain the relatively lower rates of MRSA among patients with VAP compared with other pneumonia types. Variation was present among studies in the pneumonia classification, and pneumonia diagnostic definitions were not always present. Verification bias may have occurred, in which nasal screen results influenced culture collection and/or clinical diagnosis. Moreover, the timing of the nasal swab collection in relation to the respiratory culture was not consistent or clearly defined among all studies.
There were variations MRSA pneumonia prevalence among studies, and therefore the performance of the screen may differ based on local epidemiology. However, we included conference proceedings in addition to published literature, which has been associated with more accurate pooled estimates because published trials are associated with larger produced estimates [38] . In addition, beyond pneumonia category, patient factors affecting individual risk for MRSA pneumonia, and thus affecting the pretest probability of disease, were not examined. Future studies should evaluate whether there is any impact of long-term care facilities, recent hospital admission, or other patient populations particularly at risk for MRSA pneumonia on the application of nares MRSA tests. Finally, there were a limited number of studies classifying specific pneumonia types, although screen performance was high among all types except VAP.
In conclusion, although a positive MRSA nares test result is not diagnostic of MRSA pneumonia, a negative result rapidly and effectively rules it out. MRSA nares screening, is a valuable tool for ASPs to deescalate empiric anti-MRSA therapy in patients with pneumonia who are not nasally colonized with MRSA, specifically those with CAP/HCAP. MRSA screening offers a rapid, inexpensive way for hospitals to avoid unnecessary and costly therapy that does not provide additional clinical benefit to the patient. With new IDSA CAP guidelines under development, consideration should be given to incorporating MRSA nares screening for ASP and diagnostic purposes. Additional studies are needed to fully evaluate the clinical outcomes associated with use of MRSA nares screens in patients with pneumonia.
